Moreover, despite the celebrated success of BCR/ABL fusion gene inhibition in chronic myeloid leukemia patients, continuous treatment occasionally produces drug resistance via acquisition of novel BCR/ABL mutations [170] or alternative mechanisms, and the leukemia stem cells seem to be resistant to BCR/ABL inhibitors [171]. This evidence concerns the gene BCR and leukemia.